JPS60237018A - Composition having adhesivity to interior of oral cavity - Google Patents

Composition having adhesivity to interior of oral cavity

Info

Publication number
JPS60237018A
JPS60237018A JP9337084A JP9337084A JPS60237018A JP S60237018 A JPS60237018 A JP S60237018A JP 9337084 A JP9337084 A JP 9337084A JP 9337084 A JP9337084 A JP 9337084A JP S60237018 A JPS60237018 A JP S60237018A
Authority
JP
Japan
Prior art keywords
composition
drug
oral cavity
interior
adhesivity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9337084A
Other languages
Japanese (ja)
Inventor
Yoji Iwayama
岩山 陽治
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TANPEI SEIYAKU KK
Original Assignee
TANPEI SEIYAKU KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TANPEI SEIYAKU KK filed Critical TANPEI SEIYAKU KK
Priority to JP9337084A priority Critical patent/JPS60237018A/en
Publication of JPS60237018A publication Critical patent/JPS60237018A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8147Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Abstract

PURPOSE:The titled composition having more improved adhesivity, durability of adhesion state and sustained release properties than well-known pharmaceutical preparations, obtained by adding paste or a thickening agent and a drug to a well-known carboxyvinyl polymer as a base materialf for a dental analgesic. CONSTITUTION:A composition having adhesivity to the interior of oral cavity comprising >=20wt% based on total amount of the composition of carboxyvinyl polymer, 2-50wt% another paste or a thickening agent (e.g., CMC-Na, gum arabic, MC, etc.) and a proper amount of drug. All drugs applicable to the mucosa through the oral cavity may be used as the drug. For example, drugs for central nervous system, deodorants, remedy for stomatitis, etc. may be cited as the drug. This composition is formed into a shape such as a small-sized lamellar form, spherical form, etc. suitable for adhesion to the interior of the oral cavity. A carboxyvinyl polymer is used as a base material for having adhesivity to the interior of the oral cavity, and addition of the thickening agent or paste to it can regulate release and absorption rate of the drug.

Description

【発明の詳細な説明】 本発明はヒトの口腔粘膜に付着して薬効その他の効果を
奏する組成物の改良に関する。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to improvements in compositions that adhere to human oral mucosa and exhibit medicinal and other effects.

口腔内の粘n@に411着させることにより口内炎のよ
うな粘膜疾患を治療したり又は口内粘膜を経由して薬剤
を体内に吸収させようとする試みはかなり古くから行わ
れている。これらの薬剤の原理はポリアクリル酸ナトリ
ウム(特開昭5l−38412)、ヒドロキシプロピル
セルローズもしくはポリエチレングリコール(特開昭4
9−133519)又はポリアクリル酸もしくはそのt
lとヒドロキシプロピルセルロース(特開昭54−41
320)などの親水性ゲルを主剤とし、この中に適当な
薬剤を含有させたものである。
Attempts have been made for a long time to treat mucosal diseases such as stomatitis or to allow drugs to be absorbed into the body via the oral mucosa by attaching them to mucous membranes in the oral cavity. The principle of these drugs is sodium polyacrylate (Japanese Patent Laid-Open No. 51-38412), hydroxypropyl cellulose or polyethylene glycol (Japanese Patent Laid-open No. 4
9-133519) or polyacrylic acid or its t
l and hydroxypropylcellulose (JP-A-54-41
The main ingredient is a hydrophilic gel such as 320), which contains an appropriate drug.

しかし実際にこれらの発明を追試してみると所期の効果
を奏するものは存しない。例えば、最も新しい最後者の
発明は、実際にトリアムシメロンアセトニドを含む付着
型アフタ口内炎治療剤として実施もされているが、実際
に口内粘膜に適用すると付着が困難であることに加え、
殆ど2時間以内に消失し、特に投薬後飲食したような場
合にはより速やかに消失してしまう。従って、主目的で
ある持続的な薬剤の作用はあまり期待できない。
However, when these inventions are actually tried again, none of them have the desired effect. For example, the latest and last invention has actually been implemented as an adhesive-type aphthous stomatitis treatment containing triamcimerone acetonide, but in addition to being difficult to adhere when actually applied to the oral mucosa.
It usually disappears within 2 hours, especially if you eat or drink after taking the medication. Therefore, sustained drug action, which is the main objective, cannot be expected very much.

そもそもこの種の薬剤の目的は口内粘膜を介してなるべ
く長時間薬剤を作用させることにあるから、僅か2時間
程度の持続性では目的」1明らかに不充分である。本発
明は、従来口内付着性組成物用としてこれまで利用され
たことのない親水性ポリマー物質を用いて、従来のもの
より遥に長い持続性を有する新規な口内付着性組成物を
提供することを目的とするものである。
In the first place, the purpose of this type of drug is to have the drug act for as long as possible through the oral mucosa, so a persistence of only about 2 hours is clearly insufficient for the purpose. The present invention uses hydrophilic polymeric materials that have not been previously utilized for oral adhesive compositions to provide novel oral adhesive compositions that have a much longer persistence than conventional oral adhesive compositions. The purpose is to

木発明者らは、r1中用剤の新規剤型について従来から
組織的な研究を行ってきた者であるが1本研究の一環と
して先に特開昭56−139415壮の発明をし、カル
ボキシビニルポリマー(一般名:カルボキシポリメチレ
ン;商品名:カーポポール(CARBOPOL))がゲ
ル状の歯科用鎮痛剤基材として極めて適当であることを
発見した。そしてこの発明はその後くコンジスイQ〉な
る商品名の歯科用鎮痛剤として製品化されている。
The inventors of the tree have been conducting systematic research on new formulations of R1 medicinal preparations, and as part of this research, they had previously made an invention in Japanese Patent Application Laid-Open No. 139415/1983, and discovered that carboxylic It has been discovered that a vinyl polymer (common name: carboxypolymethylene; trade name: CARBOPOL) is highly suitable as a gel dental analgesic base. This invention was subsequently commercialized as a dental analgesic under the trade name Konjisui Q.

しかるにその後の研究の結果、上のカルボキシビニルポ
リマーが単に歯科用鎮痛剤基材としてに限らず、口腔内
付着型製剤の基材として非常に優れているのみならず、
これと増粘剤又は糊剤を併用することにより、薬剤の放
出乃至吸収速度を自由に制御できるという知見が得られ
た。
However, as a result of subsequent research, the above carboxyvinyl polymer was not only excellent as a base material for dental analgesics, but also as a base material for oral preparations.
It has been found that by using this in combination with a thickening agent or a thickening agent, the release and absorption rate of the drug can be freely controlled.

本発明者の知見によれば、カルボキシビニルポリマーの
単独では成型が困難であるが、これにカルボキシメチル
セルローズナトリウム、繊維素グリコール酸ナトリウム
、アルギン酸ナトリウム、アラビアゴム、トラガントゴ
ム、グアガム、キサンタンガム、タラガム、プルラン、
メチルセルロースなどの医薬品製剤及び食品加工用の糊
剤又は増粘剤を添加すると成型が容易となるのみならず
口腔内粘膜に対する粘着性が増大し、更にデキストリン
、乳糖、白糖、ブドウ糖、微結晶セルロース、炭酸カル
シウム、ケイ酸カルシウム等の常用賦形剤を併用するこ
とにより、配合された主剤との兼合いで一層向上する。
According to the findings of the present inventor, it is difficult to mold carboxyvinyl polymer alone, but carboxymethylcellulose sodium, cellulose sodium glycolate, sodium alginate, gum arabic, gum tragacanth, guar gum, xanthan gum, tara gum, pullulan, etc. ,
Adding glue or thickeners for pharmaceutical preparations and food processing, such as methylcellulose, not only makes molding easier, but also increases the adhesion to the oral mucosa. By using commonly used excipients such as calcium carbonate and calcium silicate, the performance in combination with the main ingredient can be further improved.

因に、カルボキシビニルポリマーと常用賦形剤との組成
物では、カルボキシビニルポリマー自体の酸性のため、
主剤がアロカロイドのような塩基性物質であるとき生物
学的利用性(パイオアバイラビリティ−)が低ドするが
、この欠点も糊剤又は増粘剤の併用により改善ぎれるこ
とか見出された。以下、発明者の行なった実験の結果を
第1表として示す。各実験を通じ、試験用製剤の成型に
は乾式打錠法を用い、モンサンド硬度計で硬度的20と
なるように打錠した。なお、使用した賦形剤は、約0.
3%のステアリン酸カルシウム(滑沢剤)を除き白糖、
乳糖又はブドウ糖である。
Incidentally, in the composition of carboxyvinyl polymer and common excipients, due to the acidity of the carboxyvinyl polymer itself,
When the main ingredient is a basic substance such as an allocaloid, bioavailability is low, but it has been found that this drawback can also be improved by using a glue or thickener in combination. Table 1 below shows the results of experiments conducted by the inventor. Throughout each experiment, a dry tableting method was used to form the test preparations, and the tablets were compressed to a hardness of 20 on the Monsando hardness tester. The excipient used was approximately 0.
White sugar, excluding 3% calcium stearate (lubricant),
Lactose or glucose.

(以下余白) 第1表 因に、上の第1表の実験における持続性は次のようにし
て測定した。
(The following is a blank space) In Table 1, sustainability in the experiment shown in Table 1 above was measured as follows.

上表の組成物を錠剤製造機を用いて直径9mmφ、厚さ
2ml11.硬度的20(モンサント硬度計)、重さ約
150mgの円盤形に打錠した。別に、熱湯901にゼ
ラチン10gを溶解した溶液をスライドグラス上に3f
fi諧厚さに展延、凝固させて粘膜モデルを作った。
The composition shown in the table above was prepared using a tablet making machine to a diameter of 9 mmφ and a thickness of 2 ml11. It was compressed into disc-shaped tablets with a hardness of 20 (Monsanto hardness scale) and a weight of about 150 mg. Separately, place a solution of 10 g of gelatin in 901 boiling water on a slide glass for 3 f.
A mucous membrane model was created by spreading and coagulating it to a fi-dimensional thickness.

以」二の試験錠剤の片面に生理食塩水を一滴落としてこ
れを」二記ゼラチン膜上に圧着した後、生理食塩水30
0m1を入れたビーカー中に懸垂し、下方からマグネチ
ックスターラーで緩やかに撹拌した。このようにして、
各試験錠剤が徐々に111潤、軟化して遂にスライドグ
ラスから剥離、落下するまでの時間を測定した。各実験
を同一の錠剤毎に数回づつ反復し、得られた結果の平均
をもって持続時間とした。結果を以下第2表として示す
Drop one drop of physiological saline on one side of the test tablet described above and press it onto the gelatin membrane described in Section 2.
The mixture was suspended in a beaker containing 0 ml of water and gently stirred from below using a magnetic stirrer. In this way,
The time taken for each test tablet to gradually soften and peel off from the slide glass was measured. Each experiment was repeated several times using the same tablet, and the average of the results was taken as the duration. The results are shown in Table 2 below.

第2表 」二表の結果は、処方や錠剤の形状が変化すれば当然変
動し、その付着性や膨潤状況が変って来るが、極めて持
続性に富むことは容易に窺知される。実際上、試験錠剤
を口腔内粘膜に付着させると、8時間又はそれ以上にも
達する付着成績が得られた。この結果からも、本発明組
成物が口腔内付着性組成物として卓越した性能を備える
ことが推定される。
Table 2 The results in Table 2 will naturally vary if the formulation or shape of the tablet changes, and the adhesion and swelling state will change, but it is easy to see that it is extremely long-lasting. In fact, when the test tablets were applied to the oral mucosa, adhesion lasting up to 8 hours or more was obtained. From this result as well, it is estimated that the composition of the present invention has excellent performance as an oral adhesive composition.

次に本発明組成物の別の目的である徐放性効果、殊に内
容薬剤が同一の速度で放出されることを確かめんがため
、発明者は次のモデル実験を実施した。即ち、付着持続
性試験に使用したゼラチンゲル膜の付着したスライドグ
ラス各一枚に試験錠剤各1個を付着させた後、37℃の
生理食塩水100m1を入れたビーカ内に浸し、マグネ
チックスターラーで撹拌しながら最初の30分目、続く
1時間目及びその後の各1時間毎に生理食塩水を交換し
、各生理食塩水中に溶出ぎれた酸性色素(例えば食用色
素赤色3号など)、塩基性色素(例えばツクシン、メチ
レンブルーなど)、植物性色素(カロチン、銅クロロフ
イリンナトリウムなど)及びその他の薬剤の量を測定し
た。前記試験錠剤AT、AY及びDTについての結果を
第1図〜第3図として掲げる。図から明白なように、い
ずれも溶出速度は最初比較的急速に最高に達し、次いで
長い最大期間を経てその後次第に低下する傾向が見られ
るが、いずれにしても長時間に亘って効力を持続するこ
とが窺われる。
Next, in order to confirm the sustained release effect, which is another objective of the composition of the present invention, and in particular to confirm that the drug content is released at the same rate, the inventor conducted the following model experiment. That is, one test tablet was attached to each slide glass with a gelatin gel film used in the adhesion durability test, and then immersed in a beaker containing 100 ml of physiological saline at 37°C, and placed in a magnetic stirrer. While stirring, replace the physiological saline solution for the first 30 minutes, the following hour, and every hour thereafter, and remove any acidic dyes (such as food coloring red No. 3) and bases that have eluted into each physiological saline solution. The amounts of sex pigments (eg, tsuksin, methylene blue, etc.), vegetable pigments (carotene, sodium copper chlorophyllin, etc.), and other drugs were measured. The results for the test tablets AT, AY, and DT are shown in Figures 1 to 3. As is clear from the figure, the elution rate in each case reaches its maximum relatively quickly at first, then after a long maximum period, there is a tendency to gradually decrease, but in any case, the efficacy remains for a long time. It can be seen that.

以」二基実験の結果を総合すると、本発明に係るる口腔
内付着性組成物は1口腔内材着投与用の製剤として、粘
着性、粘着状態持続性及び徐放性のいずれにおいても公
知の製剤に優越する性能を有し、口腔内付着投与による
徐放性を期待する各種の目的に適用Sれうるものである
と結論される。
Combining the results of the two experiments below, it can be concluded that the oral adhesive composition according to the present invention is one of the well-known formulations for intraoral administration in terms of adhesiveness, persistence of adhesive state, and sustained release properties. It is concluded that this product has superior performance to other formulations, and can be applied to various purposes in which sustained release through intraoral adhesion administration is expected.

本発明に係る口腔内付着組成物は、口腔内粘膜に対し良
好な付着性を有し、本組成物の成形物を頬又は唇部分内
面に押付けると直ちに粘着して長時間に亘り該部分に付
着して内部の薬剤等の有効成分を徐々に放出し、途中飲
食しても崩壊したり又は剥離したりする恐れがない。こ
の点は従来同種薬剤に比べて極めて優れた点である。
The oral adhesive composition according to the present invention has good adhesion to the oral mucosa, and when a molded product of the composition is pressed against the inner surface of the cheek or lip area, it immediately adheres and remains in the area for a long time. It adheres to the inside and gradually releases the active ingredients such as medicines inside, and there is no risk of it disintegrating or peeling off even if you eat or drink it during the process. This point is extremely superior to conventional drugs of the same type.

本発明組成物は、目的に応じて半球形、半楕円球形、扁
平円盤形、扁平楕円球形、その他の口腔内投与に適した
形状に賦形される。成型には乾式法(直接打錠法又は間
接打錠法−一例えばスラグ法、圧延法などm−)及び湿
式法のいずれをも利用できるが、可能な限り乾式法、殊
に直接打錠法を利用するのがよい。製剤の大きさは患者
に異物感を与えないため、径ICl1以下の小型である
のを可とする。
The composition of the present invention may be shaped into a hemisphere, semi-ellipsoid, flat disc, flat ellipsoid, or other shape suitable for oral administration depending on the purpose. For molding, both dry methods (direct tableting method or indirect tableting method - e.g. slug method, rolling method, etc.) and wet methods can be used, but dry methods are used as much as possible, especially direct tabletting methods. It is better to use The size of the preparation may be small, with a diameter of ICl1 or less, so as not to give a foreign body sensation to the patient.

本発明組成物に添加される薬剤としては、自体全身性で
あると局所性であるとを問わず、経口膣粘膜的に適用可
能な一切の薬剤が対象となる。例えば解熱鎮痛剤などの
中枢神経用薬剤、自律神経剤などの末梢神経用薬剤、抗
ヒスタミン剤などのアレルギー用薬剤、血圧降下剤など
の循環器官用薬剤、鎮咳剤などの呼吸器官用薬剤、口内
炎治療剤、口中清涼剤又は口臭除去剤などの消化器官用
薬剤、ホルモン剤、ビタミン剤、嫌煙剤又は酵素製剤な
どの代謝性薬剤、腫瘍治療用薬剤、抗生物質製剤、化学
療法剤などはその主要な例であるが、勿論これらに限定
されるものではない。
The drugs to be added to the composition of the present invention include all drugs that can be applied orally or vaginally, regardless of whether they are systemic or local. For example, drugs for the central nervous system such as antipyretic analgesics, drugs for peripheral nerves such as autonomic nerve agents, drugs for allergies such as antihistamines, drugs for the circulatory system such as antihypertensive agents, drugs for the respiratory system such as antitussives, drugs for treating stomatitis, Major examples include gastrointestinal drugs such as mouth fresheners or breath odor removers, metabolic drugs such as hormones, vitamins, antismoke agents or enzyme preparations, tumor treatment drugs, antibiotic preparations, and chemotherapy drugs. However, it is of course not limited to these.

賦形剤としては白糖、乳糖、澱粉、デキストリン、シク
ロデキストリン、微結晶セルロース等の慣用の賦形剤を
利用できるが、文−メンI・−ルや丁字油その他の精油
又はビタミンEもしくはビタミンAなどの油状成分を配
合する場合はデキストリン又はシクロデキストリンのよ
うな包摂性賦形剤が女工ましい。
As the excipient, conventional excipients such as white sugar, lactose, starch, dextrin, cyclodextrin, microcrystalline cellulose, etc. can be used; When incorporating an oily component such as dextrin or cyclodextrin, an inclusive excipient such as dextrin or cyclodextrin is preferable.

糊剤又は増粘剤(粘着性成分)としては、前述のように
I・ラカントガム、コロシンI・ガム、アラヒアガム、
グアガム、クイーンスラントガム、タラカム、キサンタ
ンガムその他の各種の天然ガム類、CMCナトリウム又
はメチルセルロース又は繊維素グリコール酸ナトリウム
のような繊維素誘導体、アルギン酸ナトリウム、プルラ
ン等が使用される。これらの成分の含量は、組成物中2
〜50%の範囲である。
As the glue or thickener (adhesive component), as mentioned above, I. Lakanto gum, Colocin I. gum, Arahia gum,
Various natural gums such as guar gum, queen slant gum, taracum, xanthan gum, CMC sodium or cellulose derivatives such as methyl cellulose or cellulose sodium glycolate, sodium alginate, pullulan, etc. are used. The content of these ingredients in the composition is 2
~50% range.

滑沢剤としては普通0.3%前後のステアリン酸カルシ
ウムもしくはステアリン酸マグネシウム、1 5〆′−一\、 ポリ エチレングリコール又はタルクが添加ネれる。適
量の滑沢剤の使用により、多くの場合直接打錠が可能と
なり生産性が向にする。
As a lubricant, around 0.3% of calcium stearate or magnesium stearate, polyethylene glycol or talc is usually added. The use of appropriate amounts of lubricants often allows direct compression and improves productivity.

カルボキシビニルポリマーは通常25〜40%の範囲で
添加される。本成分の量が20%以下のときは[]的と
する持続性が充分には発揮されない。以下、実施例を掲
げ、発明実施の態様を説明するが、例示は当然説明用の
ものであって、発明精神の限定を意味するものではなく
、目的に応じて広範囲の変形を包含するものであること
は自明あ でる。
Carboxyvinyl polymer is usually added in a range of 25 to 40%. If the amount of this component is less than 20%, the desired sustainability will not be achieved sufficiently. Hereinafter, the mode of carrying out the invention will be described by way of examples, but the examples are of course for illustrative purposes only and do not mean a limitation on the spirit of the invention, and include a wide range of modifications depending on the purpose. One thing is obvious.

実施例 カルポキシビこルポリマー(カーポポール940 )4
0 g、CMCナトリウム40g、銅クロロフイリンナ
トリウム2g、包摂メントール17g及びステアリン酸
カルシウム1gをよく混合した後、直接打錠式錠剤製造
機を用いて計8ffllllφ、厚さ0.8 mm、重
量的180mg、硬度的22の扁平錠を製造した。
Example Carpoxyvinyl polymer (Carpopol 940) 4
After thoroughly mixing 0 g, CMC sodium 40 g, copper chlorophyllin sodium 2 g, menthol inclusion 17 g and calcium stearate 1 g, a total of 8 ffllllφ, thickness 0.8 mm, weight 180 mg, using a direct compression tablet making machine, Flat tablets with a hardness of 22 were manufactured.

以」−の錠剤は口腔内の粘膜によく付着する2 が、小型であるため適用者に対し殆ど異物感を感ぜしめ
ない。そして5〜7時間の長時間に11って11臭を防
市しうるのみならす本人にも快い清涼感を!j−える理
想的な口中清涼剤である。
The tablets listed below adhere well to the mucous membranes in the oral cavity, but because they are small, they hardly give the user the sensation of a foreign body. And not only can it eliminate 11 odors for a long time of 5 to 7 hours, but it also provides a pleasant refreshing feeling to the person who uses it! It is an ideal mouth freshener.

【図面の簡単な説明】[Brief explanation of drawings]

第1図〜第3図は、本発明組成物により製造ごれた「1
腔内伺着投1j−川製剤から夫々別個の薬剤が溶出する
状況を示すグラフである。 ツノg/% 0 12349 56 時間 刀2図 戸g/% 0 1 2 8 4、 5 6 11、市11
Figures 1 to 3 show "1" produced using the composition of the present invention.
It is a graph showing the elution of different drugs from the intracavitary injection 1j-river preparation. Horn g/% 0 12349 56 Time sword 2 Zudo g/% 0 1 2 8 4, 5 6 11, City 11

Claims (1)

【特許請求の範囲】 ]1] 全組成物中20%以上のカルボキシビニルポリ
マーとその他の糊料又は増粘剤を2〜50%及び適量の
薬剤を含有することを特徴とする口腔内付着性組成物。 〔2] 薬剤が対粘膜的に作用し又は経粘膜的に吸収ご
れ又は口内の臭気を除去しもしくはマスクするものであ
る特許請求の範囲第1項記載の組成物。 (3) 全体が小型の板状、球状、円錐状、楕円球状、
トーラス状、その他口内に付着せしめらd2のに適した
形状を与えられている特許請求の範囲第1項又は第2項
記載の組成物。 14[薬剤が組成物中から徐々に放出される特許請求の
範囲第1項から第3項のいずれかに記載の組成物。
[Scope of Claims] 1] Oral adhesive, characterized by containing 20% or more of a carboxyvinyl polymer, 2 to 50% of other glue or thickener, and an appropriate amount of a drug in the entire composition. Composition. [2] The composition according to claim 1, wherein the drug acts mucosally or transmucosally to remove or mask dirt or oral odor. (3) The whole is small plate-like, spherical, conical, ellipsoidal,
3. The composition according to claim 1 or 2, which has a toroidal shape or other shape suitable for adhering to the inside of the mouth. 14 [The composition according to any one of claims 1 to 3, wherein the drug is gradually released from the composition.
JP9337084A 1984-05-09 1984-05-09 Composition having adhesivity to interior of oral cavity Pending JPS60237018A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP9337084A JPS60237018A (en) 1984-05-09 1984-05-09 Composition having adhesivity to interior of oral cavity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9337084A JPS60237018A (en) 1984-05-09 1984-05-09 Composition having adhesivity to interior of oral cavity

Publications (1)

Publication Number Publication Date
JPS60237018A true JPS60237018A (en) 1985-11-25

Family

ID=14080407

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9337084A Pending JPS60237018A (en) 1984-05-09 1984-05-09 Composition having adhesivity to interior of oral cavity

Country Status (1)

Country Link
JP (1) JPS60237018A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2651128A1 (en) * 1989-08-30 1991-03-01 Chevance Leon NEW USE OF ANTI-COMPONENTS FOR THE TREATMENT OF PERIODONTOSIS.
FR2651127A1 (en) * 1989-08-30 1991-03-01 Chevance Leon NOVEL USE OF SUBSTANCES AS ANTI-COMPONENTS AND MEDICINES CONTAINING SUCH A SUBSTANCE.
JP2020015772A (en) * 2016-02-25 2020-01-30 久光製薬株式会社 Oral cavity patch
WO2021145385A1 (en) * 2020-01-15 2021-07-22 富士フイルム株式会社 Biocompatible material, and method for producing biocompatible material

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59196814A (en) * 1983-04-21 1984-11-08 Nippon Kayaku Co Ltd Sheetlike "nifedipine(r)" pharmaceutical
JPS60215622A (en) * 1984-04-09 1985-10-29 Toyobo Co Ltd Sustained release preparation for mucosa in oral cavity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59196814A (en) * 1983-04-21 1984-11-08 Nippon Kayaku Co Ltd Sheetlike "nifedipine(r)" pharmaceutical
JPS60215622A (en) * 1984-04-09 1985-10-29 Toyobo Co Ltd Sustained release preparation for mucosa in oral cavity

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2651128A1 (en) * 1989-08-30 1991-03-01 Chevance Leon NEW USE OF ANTI-COMPONENTS FOR THE TREATMENT OF PERIODONTOSIS.
FR2651127A1 (en) * 1989-08-30 1991-03-01 Chevance Leon NOVEL USE OF SUBSTANCES AS ANTI-COMPONENTS AND MEDICINES CONTAINING SUCH A SUBSTANCE.
EP0418110A1 (en) * 1989-08-30 1991-03-20 Léon Georges Chevance Use of anticomplemental agents for the treatment of parodontoses
WO1991003239A1 (en) * 1989-08-30 1991-03-21 Chevance Leon Georges Utilization of anticomplements for the treatment of periodontosis
JP2020015772A (en) * 2016-02-25 2020-01-30 久光製薬株式会社 Oral cavity patch
WO2021145385A1 (en) * 2020-01-15 2021-07-22 富士フイルム株式会社 Biocompatible material, and method for producing biocompatible material

Similar Documents

Publication Publication Date Title
US9161909B2 (en) Adhesive compositions for the treatment of xerostomia
US5637313A (en) Chewable dosage forms
EP1274398B1 (en) Methods for thepreparation of effervescent granules
US20010006677A1 (en) Effervescence polymeric film drug delivery system
JP4802436B2 (en) Orally disintegrating composition and orally disintegrating preparation
JPS62707B2 (en)
US11033589B2 (en) Oral dosage form
JP2002522471A (en) Orally disintegrating tablet forming viscous slurry
GB2042888A (en) Preparation for administration to the mucosa of the oral or nasal cavity
JP2002522471A5 (en)
US20080085248A1 (en) Controlled Long Acting Release Pharmaceutical Preparation For Use In The Oral Cavity
NZ231923A (en) Adhesive tablet comprising baclofen in a hydrophilic core with a hydrophobic coating
TW200950821A (en) Tablettable chewing gums
JPH10182436A (en) Solid medicinal preparation
CN1950068A (en) Rapidly disintegrating tablets comprising titanium dioxide
RU2440100C2 (en) New pharmaceutical compositions effective in treating parkinson's disease
JP3064417B2 (en) Controlled release formulations and methods
US20090053309A1 (en) Adhesive compositions for the treatment of xerostomia
US20030147947A1 (en) Orodispersible solid pharmaceutical form
JPS6393710A (en) Slow release fluoride composition
JPS60237018A (en) Composition having adhesivity to interior of oral cavity
JPH0130804B2 (en)
JP2000063268A (en) Oral mucosa adhesion-type controlled release troche and periodontal disease therapeutic agent
JP3515761B2 (en) Oral moisturizer for dentures
CN114159184A (en) Indicator and dental device with controlled release formulation